Month: March 2025

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1] The…

SAN DIEGO, March 9, 2025 /PRNewswire/ — Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired e.l.f. Beauty, Inc. (NYSE: ELF) securities between November 1, 2023 and November 19, 2024. e.l.f., together with its…

BOSTON, March 9, 2025 /PRNewswire/ — OnPoint AR-AI, a group of privately held augmented reality (AR) technology companies pioneering AR guidance and machine learning for neurosurgical and orthopedic spinal procedures, including robotic procedures, today announced that it will participate…